Seeing Is Believing
Currently out of the existing stock ratings of Silvan Tuerkcan, 125 are a BUY (98.43%), 2 are a HOLD (1.57%).
Analyst Silvan Tuerkcan, currently employed at JMP, carries an average stock price target met ratio of 49.87% that have a potential upside of 53.94% achieved within 135 days.
Silvan Tuerkcan’s has documented 249 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TSHA, Taysha Gene Therapies at 12-Nov-2024.
Analyst best performing recommendations are on LOGC (LOGICBIO THERAPEUTICS).
The best stock recommendation documented was for MRTX (MIRATI THER) at 9/28/2023. The price target of $58 was fulfilled within 7 days with a profit of $12.65 (27.89%) receiving and performance score of 39.85.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$34
$-0.45 (-1.31%)
$34
21 days ago
(30-Oct-2024)
8/8 (100%)
$1.56 (4.81%)
159
Buy
$33
$-1.45 (-4.21%)
$30
21 days ago
(30-Oct-2024)
13/13 (100%)
$0.56 (1.73%)
459
Buy
$38
$3.55 (10.30%)
$33
21 days ago
(30-Oct-2024)
6/9 (66.67%)
$5.56 (17.14%)
849
Buy
$34
$-0.45 (-1.31%)
$27
30 days ago
(21-Oct-2024)
7/7 (100%)
$5.34 (18.63%)
431
Buy
$34
$-0.45 (-1.31%)
$29
1 months 4 days ago
(16-Oct-2024)
17/17 (100%)
$4.65 (15.84%)
534
Which stock is Silvan Tuerkcan is most bullish on?
Which stock is Silvan Tuerkcan is most reserved on?
What Year was the first public recommendation made by Silvan Tuerkcan?